147 related articles for article (PubMed ID: 10520836)
1. Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study.
Pisegna JR; Martin P; McKeand W; Ohning G; Walsh JH; Paul J
Am J Gastroenterol; 1999 Oct; 94(10):2874-80. PubMed ID: 10520836
[TBL] [Abstract][Full Text] [Related]
2. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Metz DC; Forsmark C; Lew EA; Starr JA; Soffer EF; Bochenek W; Pisegna JR
Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936
[TBL] [Abstract][Full Text] [Related]
3. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease.
Metz DC; Pratha V; Martin P; Paul J; Maton PN; Lew E; Pisegna JR
Am J Gastroenterol; 2000 Mar; 95(3):626-33. PubMed ID: 10710049
[TBL] [Abstract][Full Text] [Related]
4. Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion.
Metz DC; Soffer E; Forsmark CE; Cryer B; Chey W; Bochenek W; Pisegna JR
Am J Gastroenterol; 2003 Feb; 98(2):301-7. PubMed ID: 12591045
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of pentagastrin-stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults.
Pratha VS; Hogan DL; Lane JR; Williams PJ; Burton MS; Lynn RB; Karlstadt RG
Dig Dis Sci; 2006 Jan; 51(1):123-31. PubMed ID: 16416224
[TBL] [Abstract][Full Text] [Related]
6. Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers.
Simon B; Müller P; Hartmann M; Bliesath H; Lühmann R; Huber R; Bohnenkamp W; Wurst W
Z Gastroenterol; 1990 Sep; 28(9):443-7. PubMed ID: 2177296
[TBL] [Abstract][Full Text] [Related]
7. Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion.
Dammann HG; Burkhardt F
Eur J Gastroenterol Hepatol; 1999 Nov; 11(11):1277-82. PubMed ID: 10563540
[TBL] [Abstract][Full Text] [Related]
8. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.
Ramdani A; Mignon M; Samoyeau R
Gastroenterol Clin Biol; 2002 Apr; 26(4):355-9. PubMed ID: 12070410
[TBL] [Abstract][Full Text] [Related]
9. Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human study.
Metz DC; Ferron GM; Paul J; Turner MB; Soffer E; Pisegna JR; Bochenek WJ
J Clin Pharmacol; 2002 May; 42(5):512-9. PubMed ID: 12017345
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and safety of intravenously administered pantoprazole in the treatment of gastrinoma].
Modlin IM
Recenti Prog Med; 2001; 92(7-8):456-61. PubMed ID: 11475787
[TBL] [Abstract][Full Text] [Related]
11. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Lew EA; Pisegna JR; Starr JA; Soffer EF; Forsmark C; Modlin IM; Walsh JH; Beg M; Bochenek W; Metz DC
Gastroenterology; 2000 Apr; 118(4):696-704. PubMed ID: 10734021
[TBL] [Abstract][Full Text] [Related]
12. Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects.
Koop H; Kuly S; Flüg M; Eissele R; Mönnikes H; Rose K; Lühmann R; Schneider A; Fischer R; Arnold R
Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):915-8. PubMed ID: 8889461
[TBL] [Abstract][Full Text] [Related]
13. Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.
Miner PB; Tutuian R; Castell DO; Liu S; Sostek MB
Clin Ther; 2006 May; 28(5):725-33. PubMed ID: 16861094
[TBL] [Abstract][Full Text] [Related]
14. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
Kwon D; Chae JB; Park CW; Kim YS; Lee SM; Kim EJ; Huh IH; Kim DY; Cho KD
Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936
[TBL] [Abstract][Full Text] [Related]
15. The novel proton pump inhibitor pantoprazole elevates intragastric pH for a prolonged period when administered under conditions of stimulated gastric acid secretion in the gastric fistula dog.
Postius S; Bräuer U; Kromer W
Life Sci; 1991; 49(14):1047-52. PubMed ID: 1832475
[TBL] [Abstract][Full Text] [Related]
16. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
Freston J; Chiu YL; Pan WJ; Lukasik N; Täubel J
Am J Gastroenterol; 2001 Jul; 96(7):2058-65. PubMed ID: 11467632
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats.
Ferron GM; McKeand W; Mayer PR
J Clin Pharmacol; 2001 Feb; 41(2):149-56. PubMed ID: 11210394
[TBL] [Abstract][Full Text] [Related]
18. Potential uses of intravenous proton pump inhibitors to control gastric acid secretion.
Metz DC
Digestion; 2000; 62(2-3):73-81. PubMed ID: 11025353
[TBL] [Abstract][Full Text] [Related]
19. Single intravenous administration of the H+, K(+)-ATPase inhibitor BY 1023/SK&F 96022--inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man.
Simon B; Müller P; Bliesath H; Lühmann R; Hartmann M; Huber R; Wurst W
Aliment Pharmacol Ther; 1990 Jun; 4(3):239-45. PubMed ID: 1966542
[TBL] [Abstract][Full Text] [Related]
20. Reduction of pentagastrin stimulated acid output: a suitable method to predict efficacy of an irreversible proton pump inhibitor in peptic ulcer disease?
Bliesath H; Simon B; Hartmann M; Müller P; Schneider A; Lühmann R; Wurst W
Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):439. PubMed ID: 1337063
[No Abstract] [Full Text] [Related]
[Next] [New Search]